EGFR and cancer: Nevertheless, a deeper and comprehensive understanding of AngII–AGTR1 axis and AGTR1–EGFR crosstalk in the context of AGTR1 positive cancers may direct future studies, which may lead to the development of novel drug targets against these pathways as an alternative to existing cancer therapies.